Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?

VanEck Biotech ETF (BBH) emphasizes concentration in 25 large biotech names (top holdings: Amgen 15.1%, Gilead 12.8%, Vertex 9.1%) versus Invesco’s broader, equal-weight healthcare exposure (RSPH holds 60 names; largest: Moderna 2.5%, Bio-Techne 2.2%, Charles River 2%). BBH is cheaper (0.35% vs 0.40% expense ratio) and has higher near-term total returns (9.8% 3-yr, 7.8% 10-yr) but comes with substantially higher 5-year max drawdown (-39.9% vs -22.0%), while RSPH offers a higher dividend yield (0.70% vs 0.50%). The article concludes BBH is the better 2026 choice for biotech exposure despite greater downside volatility.

Analysis

This is less a fundamental call on healthcare than a factor bet: BBH is a levered expression of biotech leadership, while RSPH is a de-risked basket that dilutes single-name upside. In the next 1-3 months, BBH should outperform only if market breadth stays narrow and capital keeps rewarding the same large-cap biotech incumbents; if that reverses, concentration will work against holders quickly. The main second-order effect is passive flow amplification: incremental biotech ETF inflows will disproportionately support AMGN/GILD/VRTX, while broader healthcare rotations will leak into smaller tools/life-science names like TECH and CRL via equal-weight rebalancing rather than outright earnings improvement.

The contrarian point is that the crowd may be chasing the wrong risk profile. BBH has the cleaner momentum setup, but the lower-drawdown profile of the broader basket matters if rates stay sticky or if drug-policy headlines compress biotech multiples; in that regime, concentrated biotech can underperform abruptly even without a sector-wide earnings miss. I would treat BBH as a tactical trade, not a long-duration allocation, and require either sustained relative strength versus XLV or confirmation from sector breadth before pressing size. The thesis is falsified if BBH underperforms RSPH on a 4-6 week rolling basis or if any of the large weights guide down on pipeline/regulatory risk.

Key Decisions for Investors

• Tactically long BBH vs RSPH for 4-8 weeks only if biotech relative strength remains intact; target is momentum capture, not fundamental alpha. Trim if BBH/RSPH rolls over for two consecutive weeks.
• Use RSPH as the defensive healthcare hold for 6-18 months; it is the cleaner way to own the sector if the next macro move is higher-for-longer rates or broader risk-off, with less blow-up risk than concentrated biotech.
• Watch AMGN/GILD/VRTX earnings and guidance as the real catalyst set for BBH; any guide-down from one of the top weights should be treated as a fast-fail signal and a reason to cut BBH exposure.
• If you want exposure to healthcare breadth rather than biotech beta, prefer RSPH and look for a pair trade long RSPH / short BBH on a biotech momentum failure, especially if BBH breaks its 50-day while healthcare breadth improves.
• Alert item: if biotech inflows accelerate in the next 1-3 months, expect disproportionate support in the top BBH holdings and consider scaling into BBH only on pullbacks, not strength-chasing.